Personalis (NASDAQ:PSNL) Lowered to Hold Rating by Craig Hallum

Personalis (NASDAQ:PSNL) was downgraded by equities research analysts at Craig Hallum from a “buy” rating to a “hold” rating in a research report issued on Monday. They currently have a $16.25 price target on the stock. Craig Hallum’s price objective suggests a potential downside of 11.59% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Friday, July 17th. Needham & Company LLC downgraded Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. TD Cowen reaffirmed a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Zacks Research downgraded Personalis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Finally, Lake Street Capital downgraded Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a research report on Monday, July 20th. Four analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Personalis presently has a consensus rating of “Hold” and an average target price of $14.54.

Personalis Price Performance

Shares of PSNL stock opened at $18.38 on Monday. The company’s fifty day simple moving average is $13.30 and its two-hundred day simple moving average is $9.68. Personalis has a 52 week low of $4.65 and a 52 week high of $18.89. The stock has a market cap of $1.92 billion, a P/E ratio of -16.86 and a beta of 2.27.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The firm had revenue of $22.36 million for the quarter, compared to analysts’ expectations of $16.69 million. On average, analysts anticipate that Personalis will post -1.07 EPS for the current fiscal year.

Insider Buying and Selling at Personalis

In other Personalis news, CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction on Monday, June 29th. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at $2,783,662. The trade was a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the transaction, the chief executive officer owned 235,986 shares in the company, valued at $3,558,668.88. This trade represents a 29.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 435,032 shares of company stock worth $5,599,929 in the last 90 days. 4.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Personalis

Institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd boosted its stake in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the period. International Assets Investment Management LLC purchased a new stake in Personalis in the 4th quarter worth about $31,000. Legal & General Group Plc bought a new stake in Personalis in the second quarter worth about $30,000. Quantbot Technologies LP bought a new stake in Personalis in the second quarter worth about $69,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares during the period. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.